Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794238 | 0.94 | DRD2 (0.41) | DRD2SUV39H2FNTAFNTBDRD1 | |
| SCHEMBL6792526 | 0.93 | DRD2 (0.39) | DRD2SUV39H2DRD4DRD3BRD4 | |
| SCHEMBL6788891 | 0.92 | DRD2 (0.39) | DRD2SUV39H2FNTAFNTBDRD3 | |
| SCHEMBL6793501 | 0.92 | DRD2 (0.39) | DRD2DRD4DRD3BRD4CYP11B1 | |
| SCHEMBL6793140 | 0.91 | DRD2 (0.38) | DRD2SUV39H2BRD4CYP11B1CYP11B2 | |
| SCHEMBL6792678 | 0.90 | BRD4 (0.37) | DRD2SUV39H2BRD4CYP11B1CYP11B2 | |
| SCHEMBL6792702 | 0.89 | DRD2 (0.42) | DRD2SUV39H2DRD3BRD4 | |
| SCHEMBL6787678 | 0.88 | DRD2 (0.39) | DRD2FNTAFNTBDRD1DRD4 | |
| SCHEMBL6794841 | 0.88 | DRD2 (0.40) | DRD2DRD3BRD4CYP11B1CYP11B2 | |
| SCHEMBL6797709 | 0.87 | DRD2 (0.40) | DRD2SUV39H2DRD3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DRD2 4396/4885SUV39H2 3165/4885FNTA 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.